A team led by Drs. Ryan Shields (University of Pittsburgh) and Jason Pogue (University of Michigan) has recently published the CACTUS study in The Lancet Infectious Diseases. Across 28 hospitals in the United States, investigators found higher rates of clinical success for patients treated with ceftolozane-tazobactam compared to ceftazidime-avibactam for infections caused by multidrug-resistant Pseudomonas aeruginosa. The study matched patients 1:1 at each site through an innovative design and now represents the largest real-world evidence study for treatment of MDR P. aeruginosa infections published to date.

For more information, click here.